Palvella Therapeutics (PVLA) Cash & Current Investments (2013 - 2026)
Palvella Therapeutics (PVLA) reported Cash & Current Investments of $261.9 million for Q1 2026, up 246.25% year-over-year from $75.6 million in Q1 2025, and up 351.61% on a QoQ basis from $58.0 million in Q4 2025.
Palvella Therapeutics (PVLA) has 14 years of Cash & Current Investments data on file, last reported at $261.9 million in Q1 2026.
- Quarterly Cash & Current Investments rose 246.25% year-over-year to $261.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $261.9 million (up 246.25% YoY) and the FY2025 annual result came in at $58.0 million, down 30.65% from the prior year.
- Cash & Current Investments advanced to $261.9 million in Q1 2026 per PVLA's latest filing, from $58.0 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $261.9 million in Q1 2026 and bottomed at $6.2 million in Q1 2024.
- The 5-year median for Cash & Current Investments is $63.6 million (2025), against an average of $67.3 million.
- The widest annual swing landed in 2024, when Cash & Current Investments slumped 87.09%; it then surged 1110.4% in 2025.
- Tracing PVLA's Cash & Current Investments over 5 years: stood at $59.2 million in 2022, then slumped by 72.42% to $16.3 million in 2023, then surged by 412.27% to $83.6 million in 2024, then tumbled by 30.65% to $58.0 million in 2025, then surged by 351.61% to $261.9 million in 2026.
- Per Business Quant, the three latest PVLA Cash & Current Investments figures stand at $261.9 million (Q1 2026), $58.0 million (Q4 2025), and $63.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.13 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.01 Bn |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | 261.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 261.85 Mn |
| Dec 31, 2025 | 57.98 Mn |
| Sep 30, 2025 | 63.57 Mn |
| Jun 30, 2025 | 70.43 Mn |
| Mar 31, 2025 | 75.63 Mn |
| Dec 31, 2024 | 83.60 Mn |
| Sep 30, 2024 | 14.21 Mn |
| Jun 30, 2024 | 14.54 Mn |
| Mar 31, 2024 | 6.25 Mn |
| Dec 31, 2023 | 16.32 Mn |
| Sep 30, 2023 | 56.72 Mn |
| Jun 30, 2023 | 64.84 Mn |
| Mar 31, 2023 | 48.38 Mn |
| Dec 31, 2022 | 59.17 Mn |
| Sep 30, 2022 | 69.82 Mn |
| Jun 30, 2022 | 80.94 Mn |
| Mar 31, 2022 | 100.27 Mn |
| Dec 31, 2021 | 117.76 Mn |
| Sep 30, 2021 | 34.90 Mn |
| Jun 30, 2021 | 91.80 Mn |
| Mar 31, 2021 | 66.84 Mn |
| Dec 31, 2020 | 70.44 Mn |
| Sep 30, 2020 | 82.64 Mn |
| Jun 30, 2020 | 77.21 Mn |
| Mar 31, 2020 | 86.76 Mn |
| Dec 31, 2019 | 104.15 Mn |
| Sep 30, 2019 | 86.24 Mn |
| Jun 30, 2019 | 99.68 Mn |
| Mar 31, 2019 | 110.78 Mn |
| Dec 31, 2018 | 125.18 Mn |
| Sep 30, 2018 | 137.30 Mn |
| Jun 30, 2018 | 150.98 Mn |
| Mar 31, 2018 | 159.58 Mn |
| Dec 31, 2017 | 72.63 Mn |
| Sep 30, 2017 | 89.92 Mn |
| Jun 30, 2017 | 50.32 Mn |
| Mar 31, 2017 | 55.24 Mn |
| Dec 31, 2016 | 29.36 Mn |
| Sep 30, 2016 | 36.56 Mn |
| Jun 30, 2016 | 40.37 Mn |
| Mar 31, 2016 | 31.19 Mn |
| Dec 31, 2015 | 29.35 Mn |
| Sep 30, 2015 | 32.25 Mn |
| Jun 30, 2015 | 10.03 Mn |
| Mar 31, 2015 | 13.17 Mn |
| Dec 31, 2014 | 18.47 Mn |
| Sep 30, 2014 | 936,183.00 |
| Jun 30, 2014 | 1.49 Mn |
| Mar 31, 2014 | 3.27 Mn |
| Dec 31, 2013 | 3.69 Mn |
| Sep 30, 2013 | 688.00 |
| Jun 30, 2013 | 5,200.00 |